← Back to Screener
Amylyx Pharmaceuticals, Inc. Common Stock (AMLX)
Price$17.57
Favorite Metrics
Price vs S&P 500 (26W)20.00%
Price vs S&P 500 (4W)23.45%
Market Capitalization$2.03B
All Metrics
Book Value / Share (Quarterly)$2.78
P/TBV (Annual)2.61x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)574.28%
Cash Flow / Share (Quarterly)$-1.12
Price vs S&P 500 (YTD)47.85%
Gross Margin (TTM)82.75%
Net Profit Margin (TTM)-94.56%
EPS (TTM)$-1.55
10-Day Avg Trading Volume1.42M
EPS Excl Extra (TTM)$-1.55
Revenue Growth (5Y)127.75%
EPS (Annual)$-1.53
ROI (Annual)-47.41%
Gross Margin (Annual)63.22%
Net Profit Margin (5Y Avg)-7716.48%
Cash / Share (Quarterly)$2.88
ROA (Last FY)-43.51%
EBITD / Share (TTM)$-1.62
ROE (5Y Avg)-75.43%
Operating Margin (TTM)-99.16%
Cash Flow / Share (Annual)$-1.12
P/B Ratio6.65x
P/B Ratio (Quarterly)4.35x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)9.13x
Net Interest Coverage (TTM)-10.93x
ROA (TTM)-52.17%
EV / EBITDA (TTM)45.95x
EPS Incl Extra (Annual)$-1.53
Current Ratio (Annual)14.27x
Quick Ratio (Quarterly)13.98x
3-Month Avg Trading Volume1.36M
52-Week Price Return380.63%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$6.20
P/S Ratio (Annual)23.23x
Asset Turnover (Annual)0.45x
52-Week High$18.61
Operating Margin (5Y Avg)-7253.97%
EPS Excl Extra (Annual)$-1.53
CapEx CAGR (5Y)-1.78%
26-Week Price Return28.75%
Quick Ratio (Annual)13.98x
13-Week Price Return30.49%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)14.27x
Enterprise Value$1,802.807
Revenue / Share Growth (5Y)119.26%
Asset Turnover (TTM)0.50x
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-345.81%
Cash / Share (Annual)$2.88
3-Month Return Std Dev71.10%
Net Income / Employee (TTM)$-1
ROE (Last FY)-47.41%
EPS Basic Excl Extra (Annual)$-1.53
Receivables Turnover (TTM)0.00x
EV / Free Cash Flow (TTM)410.90x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.55
Receivables Turnover (Annual)0.00x
ROI (TTM)-57.52%
P/S Ratio (TTM)10.33x
Pretax Margin (5Y Avg)-7715.61%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$5.12
Price vs S&P 500 (52W)345.53%
Year-to-Date Return51.99%
5-Day Price Return11.48%
EPS Normalized (Annual)$-1.53
ROA (5Y Avg)-64.75%
Net Profit Margin (Annual)-345.36%
Month-to-Date Return32.09%
Cash Flow / Share (TTM)$0.04
EBITD / Share (Annual)$-1.62
Operating Margin (Annual)-360.22%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-75.43%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-1.55
P/TBV (Quarterly)2.13x
P/B Ratio (Annual)4.35x
Inventory Turnover (TTM)1.68x
Pretax Margin (TTM)-93.56%
Book Value / Share (Annual)$2.78
Price vs S&P 500 (13W)27.63%
Beta0.01x
P/FCF (Annual)190.06x
Revenue / Share (TTM)$0.00
ROE (TTM)-57.52%
52-Week Low$3.79
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.38
4.38
4.38
4.33
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
AMLXAmylyx Pharmaceuticals, Inc. Common Stock | 10.33x | — | 82.75% | — | $17.57 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Amylyx Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapies for amyotrophic lateral sclerosis, neurodegenerative diseases, and endocrine disorders. The company is focused on addressing unmet medical needs in these therapeutic areas.